Faron Pharmaceuticals Oy logo

Faron Pharmaceuticals Oy(LSE) FARN

Market Cap£73.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-84%
5 Year-87%
1 Year-80%
1 Month+3%
£0.36
-0.41%
-0.00Today
Faron Pharmaceuticals Oy last closing stock price
MetricPriceDate
Last closeGBX 36.002026-10-16
Faron Pharmaceuticals Oy stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.37%GBX 36.502026-10-09
1 month+2.86%GBX 35.002026-09-16
3 month-12.2%GBX 41.002026-07-17
Year to date-80%GBX 180.002025-12-31
1 year-79.72%GBX 177.502025-10-16
3 year-85.56%GBX 249.232023-10-17
5 year-87.25%GBX 282.462021-10-15
Since inception-83.95%GBX 2.242015-11-17

Faron Pharmaceuticals Oy Financials at a Glance

Market Cap

£73.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€0.00

Net Income (TTM)

-€16.41M

EPS (TTM)

-£0.11

P/E Ratio

-3.32

Dividend

£0.00

Beta (Volatility)

0.01 (Low)

Price

£0.36

Volume

49,095

Open

£0.34

Previous Close

£0.36

Daily Range

£0.34 - £0.36

52-Week Range

£0.34 - £1.93

Estimated Earnings Date

Mar 19, 2027

FARN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy is a clinical-stage biotechnology firm based in Turku, Finland, focused on developing innovative pharmaceutical solutions. The company specializes in immune modulation to address significant unmet medical needs, with a pipeline that includes therapies for immuno-oncology, organ safeguarding, and regenerative medicine.

Products and Services
  • Traumakine: Treatment for acute respiratory distress syndrome and COVID-19
  • Bexmarilimab: Precision immunotherapy targeting solid tumors and hematological malignancies
  • Haematokine: AOC3 inhibitor for hematological malignancies and bone marrow conditions
Growth Outlook
  • Strong pipeline with multiple candidates addressing critical health issues
  • Recent funding rounds have bolstered cash reserves for ongoing research
  • Partnerships with leading institutions enhance development capabilities
Financial Highlights
  • Recent quarterly net income of -€8.56 million reflects ongoing R&D investments
  • Cash and cash equivalents of €32.15 million provide a solid financial foundation
  • Current ratio of 2.40 indicates strong liquidity position
Faron Pharmaceuticals Oy is positioned in the biotechnology sector, focusing on innovative therapies that address pressing medical challenges. The company's leading candidates, such as Traumakine and Bexmarilimab, are under investigation for various serious conditions, showcasing the potential for significant market impact. The recent financial data indicates a commitment to research and development, with substantial investments aimed at advancing its pipeline. The liquidity position, supported by a healthy cash reserve, allows for continued operational stability and growth. As the company navigates its clinical trials and partnerships, it remains a noteworthy entity in the biotechnology landscape.
AI Generated • Oct 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

33

CEO

Juho Markku Jalkanen, PhD, MD

Website

www.faron.com

Headquarters

Turku, FP 20520, FI

FARN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

476.49%

Return on Capital

-328.32%

Return on Assets

-45.51%

Earnings Yield

-30.12%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£73.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

202.88M

Volume

49.09K

Avg. Volume

62.42K

Financials (TTM)

Gross Profit

-€343.87K

Operating Income

-€19.53M

EBITDA

-€19.03M

Operating Cash Flow

-€38.32M

Capital Expenditure

€0.00

Free Cash Flow

-€38.32M

Cash & ST Invst.

€32.15M

Total Debt

€17.92M

Faron Pharmaceuticals Oy Performance Analysis

Faron Pharmaceuticals Oy annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 0N/A
20232023-12-31EUR 0N/A
20242024-12-31EUR 0N/A
20252025-12-31EUR 0N/A
Faron Pharmaceuticals Oy sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Q22026-06-30N/A
Faron Pharmaceuticals Oy annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -0.3523.6%
20232023-12-31EUR -0.33-6.8%
20242024-12-31EUR -0.24-27.6%
20252025-12-31EUR -0.21-12.4%
Faron Pharmaceuticals Oy sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3145.9%
Q22025-06-30-67.1%
Q42025-12-3120.6%
Q22026-06-3022.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€0.00

N/A

Gross Profit

-€168.93K

N/A

Gross Margin

0.00%

N/A

Market Cap

£73.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£2.21M

N/A

Employees

33

N/A

Net Income

-€8.56M

-59345.9%

EBITDA

-€10.99M

-7680.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€32.15M

+7.3%

Total Debt

€17.92M

+40.8%

Accounts Receivable

€0.00

N/A

Inventory

€0.00

N/A

Long Term Debt

€9.24M

+3.3%

Short Term Debt

€8.68M

+129.7%

Return on Assets

-45.51%

N/A

Return on Invested Capital

-89.14%

N/A

Free Cash Flow

-€12.60M

-45.0%

Operating Cash Flow

-€12.60M

-45.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BVXP.LBioventix PLC
£18.00+2.86%
HEMO.LHemogenyx Pharmaceuticals Plc
£6.58+7.17%
SAR.LSareum Holdings plc
£0.28+0.01%
SCLP.LScancell Holdings plc
£0.09-0.53%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$89.85-5.79%
NVDANvidia
$214.13-1.43%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$93.67-12.74%
CCCCCC Intelligent Solutions
$7.61-0.26%

Questions About FARN

What is the current price of Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy is trading at £0.36 per share.

What is the 52-week range for Faron Pharmaceuticals Oy?

Over the past 52 weeks, Faron Pharmaceuticals Oy has traded between £0.34 and £1.93.

How much debt does Faron Pharmaceuticals Oy have?

As of the most recent reporting period, Faron Pharmaceuticals Oy reported total debt of €21.55M.

How much cash does Faron Pharmaceuticals Oy have on hand?

Faron Pharmaceuticals Oy reported €10.75M in cash and cash equivalents in its most recent financial results.

What is Faron Pharmaceuticals Oy’s dividend yield?

Faron Pharmaceuticals Oy does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services